Author(s)

Xintang Li

Corresponding Author

Xintang Li

ABSTRACT

Coating the surface of nanoparticles with polyethylene glycol (PEG), or “PEGylation,” is a commonly used approach for improving the efficiency of drugs and gene delivery to target cells and tissues. Due to the properties of drugs, some of them are limited in clinical application. Attaching monoclonal antibodies on the surface of nanoparticles could be a potential strategy to achieve high treatment efficiency with a low side effect profile. However, the monoclonal antibody-conjugated nanoparticles showed higher efficacy compared to the normal drug-loaded nanoparticular in vitro. This review will highlight some bio-target that can be used on monoclonal antibody-conjugated nanoparticles, the result of in vivo tumor inhibition, and survival tests of those monoclonal antibody-conjugated nanoparticles.

KEYWORDS

Cancer Therapy, Nanoparticular, Monoclonal Antibody